Dragonfly Research is the research arm of The Elliot Lewis Center. Dragonfly Research is currently conducting many clinical trials for relapsing and progressive forms of multiple sclerosis. Ongoing research includes phase II and phase III clinical trials, as well as phase IV observational trials, investigating the efficacy of new and existing multiple sclerosis therapies.

The Elliot Lewis Center is actively participating in approximately 20 multiple sclerosis clinical trials. Our center participates in clinical research with approved therapies as well as treatments under study and not yet available for relapsing and progressive forms of multiple sclerosis.

Enrolling studies at Dragonfly Research change regularly, and enrollment is limited so we encourage you to contact us as soon as possible and check this page frequently. Our Clinical Research Coordinators, can be reached at 781-591-8313.

The Elliot Lewis Center and Dragonfly Research also conduct independent research projects to address important clinical issues.

Currently Enrolling…!

MUSETTE

Clinical Trial Opportunity for Patients with Relapsing Remitting Multiple Sclerosis

The Elliot Lewis Center is currently participating in a clinical trial for patients with Relapsing MS aged 18-55. Patients will receive Ocrevus for 4.5 years through the study. To be eligible patients must have at least one documented relapse in the past year, and must ambulate without assistance. Patients must NOT have received previous treatment with Ocrevus or Rituxan in the past two years.

In addition to collecting safety data, the study is evaluating the efficacy and safety of higher dose Ocrevus in adults with RMS.

The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study

GAVOTTE

Clinical Trial Opportunity for Patients with Primary Progressive Multiple Sclerosis

The Elliot Lewis Center is currently participating in a clinical trial for patients with Primary Progressive MS aged 18-55. Patients will receive Ocrevus for 4.5 years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan in the past two years.

In addition to collecting safety data, the study is evaluating the efficacy and safety of higher dose Ocrevus in adults with PPMS.

The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study

EXCHANGE
Clinical Trial Opportunity for Patients with Relapsing & Secondary Progressive MS:
Patients aged 18-65 with Relapsing or Secondary Progressive MS may be eligible for treatment with Siponimod, an investigational MS therapy.

This study is tracking the tolerability of Siponimod and any potential immune effects. Siponimod is a once-daily pill and patients will receive 6 months of treatment through the study. After completing the study, patients will have the option to receive Siponimod through a managed access program until it becomes commercially available.

Patients must currently be treated with any oral or injectable MS therapy. Certain previous MS therapies may be exclusionary. The study requires 4 visits over the course of 6 months and does not require any MRIs. The medication, assessments, and physician appointments are covered by the study.

CONSONANCE *currently not enrolling but will re-open for enrollment in Spring

Clinical Trial Opportunity for Patients with Primary Progressive & Secondary Progressive MS:
The Elliot Lewis Center is currently participating in a clinical trial for patients with Primary and Secondary Progressive MS aged 18-65. Patients will receive Ocrevus for 4 years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan.

In addition to collecting safety data, the study is investigating the use of smartphones to track patient symptoms. 75% of patients who enter the trial will receive a smartphone with daily and weekly tasks, tracking day-to-day symptoms.

The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.

Contact the research coordinators at The Elliot Lewis Center for more information.